The Effect of Hab-o-Shefa Product on craving Reduction in Outpatients with Opioid Substance Use Disorder

The Effect of Hab-o-Shefa Product on craving Reduction after Detoxification Phase in Outpatients with Opioid Substance Use Disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190817044547N1

Enrollment

Registered

2019-10-01

Start date

2019-09-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance abuse. Opioid dependence

Interventions

Intervention 1: Intervention group: The patients will receive daily oral 500 mg of Hab-o-Shefa Product for three months. Intervention 2: Control group: The patients will receive daily oral 500 mg of p

Eligibility

Sex/Gender

Male

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients with opioid addiction according to the DSM V Reference Criteria who have not had other substance use disorders such as stimulants in the past year People who can answer questions and tests Blood pressure is lower than 14.9cm Hg; There is not history of major physical and mental illness There is an equal distribution on education, occupation, and marital status between samples.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Craving after Detoxification Phase. Timepoint: At the baseline (before intervention) and monthly until end of study. Method of measurement: Obsessive Compulsive Drug use Scale questionnairy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bagher Saberi zafarghandi

Iran University of Medical Sciences

saberi.mb@iums.ac.ir+98 21 6655 1658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026